Thirteen children with hyperkalaemia were treated by intravenous infusions of salbutamol, 4 pg/kg over 20 minutes. Reductions in the mean (SD) plasma potassium concentrations, of 1-48 (0.5) and 1-64 (0-5) The six infants with acute renal failure after cardiac surgery had a mean age of 0-24 years (range 0 01-0-5), a mean weight of 4-0 kg (range 3 2-5 5), a mean serum creatinine concentration of 193 ilmoi/l (range 150-254), and a mean (SD) initial plasma potassium concentration of 6-7 (0 14) mmol/l before treatment. The initial mean plasma potassium concentration of the group with underlying renal disease and hyperkalaemia (n=7) was 6-7 (0-34) mmol/l. The mean age, weight, and plasma creatinine concentration of this group were 6-1 years
butamol by intravenous infusion to try and reduce their plasma potassium concentrations. Six infants had hyperkalaemia as a result of acute renal failure after cardiac surgery, and the remaining seven had a variety of renal disorders that culminated in hyperkahlemia (table) .
All the children were anuric at the time that the salbutamol was given. None of the children with acute renal failure were receiving adrenaline but all were on low doses of dopamine 3 1tg/ kg/minute and dobutamine, median dose 10 .tg/ kg/minute. Before 
Results
The changes in the plasma potassium concentration with time after intravenous salbutamol infusion are shown in the figure. The mean (SD) reduction in plasma potassium concentration was 1-48 (0-5) mmol/l (n= 13, p<0 001) and 1-64 (0 5) mmol/l, (n=9, p<0 001) at 40 and 120 minutes, respectively, in the whole group after completion of the salbutamol infusion.
Changes were similar in the two subgroups of patients at both 40 and 120 minutes (figure). In those children who developed acute renal failure after cardiac surgery the salbutamol infusion resulted in no significant change in heart rate (135 (10) beats/minute before infusion compared with 139 (8) during infusion), mean arterial pressure (70 (5) mmHg compared with 68 (4)), or arterial oxygen saturation (92 (4)% compared with 90 (3)%), nor was there a need to increase the inotropic support during the period of the study.
Discussion
The definitive treatment of hyperkalaemia in renal failure is to remove the excess potassium by dialysis, supplemented if necessary by ion exchange resins. It is often necessary, however, to 'buy time' for these treatments to work by inducing a shift of potassium from the extracellular to the intracellular space. This can be achieved by the intravenous administration of sodium bicarbonate, or dextrose and insulin, and 13 adrenergic stimulation also lowers the extracellular potassium concentration in this way.4 5 Recent work, however, has suggested that bicarbonate alone is slow and limited in effect,6
and there is a high incidence of hypoglycaemia associated with the use of dextrose and insulin causing some physicians to advocate the use of dextrose alone.6
02 Adrenergic stimulation is known to promote extrarenal potassium uptake4: we have used intravenous salbutamol, a 132 agonist to produce this effect. Salbutamol acts by binding to the 132 adrenergic receptors in the liver and muscle cell membranes. This then stimulates the enzyme adenylate cyclase, which increases the conversion of ATP to 3'5' cyclic AMP. This in turn acts on the sodium/potassium ATPase pump and facilities intracellular potassium uptake. 4 Stemmer et al found that nebulised salbutamol was ineffective in promoting extrarenal potassium uptake in patients with end stage renal failure,5 but we found that an intravenous infusion of salbutamol was as effective in patients with acute on chronic renal failure as in those with acute renal failure after cardiac surgery despite the different ages and different degrees of severity of renal failure within the two groups.
Lens et al have recently shown that salbutamol given intravenously was as effective as dextrose and insulin in producing a reduction in the plasma potassium concentration in patients with chronic renal failure and it had no side effects: they also showed the effects of salbutamol given intravenously and of dextrose and insulin were additive.3
We have shown that hyperkalaemia can effectively be reduced by one intravenous dose of salbutamol (4 Rg/kg) given at a constant rate over 20 minutes. The effect lasts for at least 120 minutes after the end of the infusion allowing time for dialysis to be instituted if appropriate. The treatment is safe and avoids the risk of the hypoglycaemia that is caused by the use of dextrose and insulin in infants and small children. We now recommend salbutamol infusion as the first treatment of choice in children with dangerous hyperkalaemia; it can be combined with bicarbonate, ion exchange resins, and dextrose and insulin if necessary.
intravenous salbutamol. 
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